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Abstract
RNA interference (RNAi) for anti-angiogenic or pro-apoptotic factors in endothelial cells (ECs)
has great potential for the treatment of ischemic diseases by promoting angiogenesis or inhibiting
apoptosis. Here, we report the utility of small interfering RNA (siRNA) in inhibiting EC apoptosis
induced by tumor necrosis factor-α (TNF-α). siRNA was designed and synthesized targeting
tumor necrosis factor-α receptor-1 (TNFR-1) and Src homology 2 domain-containing protein
tyrosine phosphatase-1 (SHP-1). Human umbilical vein endothelial cells (HUVECs) were cultured
under in vitro hypoxic and serum-deprived conditions to simulate in vivo ischemic conditions.
Two days after liposomal delivery of siRNA targeting TNFR-1 and SHP-1, significant silencing of
each target (TNFR-1; 76.5 % and SHP-1; 97.2 %) was detected. Under serum-deprived hypoxic
(1% oxygen) conditions, TNF-α expression in HUVECs increased relative to normoxic (20%
oxygen) and serum-containing conditions. Despite enhanced TNF-α expression, suppression of
TNFR-1 or SHP-1 by siRNA delivery not only enhanced expression of angiogenic factors (KDR/
Flk-1 and eNOS) and anti-apoptotic factor (Bcl-xL) but also reduced expression of a pro-apoptotic
factor (Bax). Transfection of TNFR-1 or SHP-1 siRNA significantly decreased the HUVEC
apoptosis while significantly enhancing HUVEC proliferation and capillary formation. The
present study demonstrates that TNFR-1 and SHP-1 may be useful targets for the treatment of
myocardial or hindlimb ischemia.
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Ischemia is associated with apoptosis of endothelial cells (ECs) due to hypoxia and
deficiency of survival growth factors [1–4]. During the ischemic event, tumor necrosis
factor-α (TNF-α) induces EC apoptosis, resulting in impaired angiogenesis [5,6]. Several
molecules are known to mediate EC apoptosis induced by TNF-α, including Src homology 2
domain-containing protein tyrosine phosphatase-1 (SHP-1) [5,6] and tumor necrosis factor-
α receptor-1 (TNFR-1) [7]. SHP-1 activated by TNF-α can inhibit EC proliferation and
angiogenesis via the inactivation of vascular endothelial growth factor (VEGF) receptor-2
(KDR/Flk-1) in ECs [5,6,8,9]. In addition to its antiangiogenic activity, SHP-1 also plays a
significant role in apoptosis in many cell types [10–12]. Previous studies have reported
upregulation of SHP-1 expression following myocardial or cerebral ischemia, which may
contribute to the increased myocardial [12] or cerebral [13] infarction. TNFR-1 is also
stimulated by TNF-α binding and negatively modulates angiogenesis through the
inactivation of KDR/Flk-1 and subsequent inhibition of EC proliferation [7,14,15]. TNFR-1
activation by TNF-α upregulated after myocardial or hindlimb ischemia impairs
angiogenesis and contributes to tissue apoptosis and the consequent progression of ischemic
diseases [14,15].
We hypothesize that the specific silencing of gene expression using RNA interference
(RNAi) could be used to interrupt anti-angiogenic and apoptotic signal pathways mediated
by SHP-1 or TNFR-1. Silencing of SHP-1 or TNFR-1 expression with small interfering
RNA (siRNA) may enhance the proliferative and angiogenic capacity of ECs and inhibit
apoptosis of ECs under in vitro and in vivo ischemic conditions, thereby facilitating rescue
of damaged tissues. Here, we examine the potential of siRNA targeting SHP-1 or TNFR-1 to
improve the proliferative and angiogenic properties of human umbilical vein endothelial




All siRNAs were synthesized by Dharmacon (Lafayette, CO, USA). Two siRNAs were
designed for targeting human TNFR-1 (GenBank accession number: NM_001065) and
human SHP-1 (GenBank accession number: NM_080548). Green Fluorescent Protein (GFP)
siRNA was used as a negative control [16]. The sequences for the sense and anti-sense
strands of siRNAs are: 1) TNFR-1, (sense) 5’-CAAAGG AAC CUA CUU GUA CUU-3’,
(anti-sense) 5’-GUA CAA GUA GGU UCC UUU GUU-3’, 2) SHP-1, (sense) 5’-
GGAACAAAU GCG UCC CAU AUU-3’, (anti-sense) 5’-UAU GGG ACG CAU UUG
UUC CUU-3’, 3) GFP, (sense) 5’-CAA GCU GAC CCU GAA GUU CUU-3’, (anti-sense)
5’-GAA CUU CAG GGU CAG CUU GUG-3’. All siRNAs were generated by annealing
equimolar amounts of complementary sense and anti-sense strands.
siRNA transfection
HUVECs (Cambrex, Walkersville, MD, USA) were cultured in EGM-2 medium (Cambrex)
supplemented with the SingleQuot kit at 37 °C and 5% CO2. HUVECs at passage three were
used for transfection. For examination of cell viability and apoptosis, HUVECs were seeded
(10,000 cells per well) into 96-well polystyrene plates (Corning-Costar, Kennebunk, ME,
USA) and allowed to attach overnight in EGM-2 medium. HUVECs were transfected with
siRNAs complexed with Lipofectamine™ 2000 (1.0 mg/ml, Invitrogen, Carlsbad, CA,
USA) as described by the vendor. Briefly, Lipofectamine diluted in serum-free Opti-MEM
(Invitrogen) was added to the siRNAs premixed with Opti-MEM at a 2.5:1 Lipofectamine-
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to-siRNA weight-weight ratio, and the mixtures were incubated for 20 min at room
temperature to allow for complex formation. The mixtures were added (50 ng of siRNA per
well) to EGM-2 medium in each well of the 96-well polystyrene plates. Growth medium
was removed from the cells, and the EGM-2 medium containing Lipofectamine/siRNA
complexes was immediately transferred to the cells. Transfection was performed in
quadruplicate. For reverse transcription-polymerase chain reaction (RT-PCR) and real-time
PCR, HUVECs seeded into each well of 6-well polystyrene plates (2.0 × 105 cells per well)
were transfected with siRNAs complexed with Lipofectamine at 2.5 (w/w) ratio of
Lipofectamine to siRNA (1 μg of siRNA per well). After transfection, cells were allowed to
grow for two days at 37 °C and 5% CO2. Transfection efficiency was determined by
measuring glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity in HUVECs 2
days after transfection with human GAPDH siRNA (Ambion, Austin, TX, USA). GAPDH
activity was measured using the KDalert™ GAPDH assay kit (Ambion) according to the
manufacture’s instructions. GAPDH activity of GAPDH siRNA-transfected HUVECs was
expressed as a percent activity to that of GFP siRNA-transfected HUVECs.
HUVEC culture under hypoxic and serum-free conditions
Two days after transfection with SHP-1, TNFR-1, or GFP siRNA, HUVECs were cultured
under hypoxic and serum-free conditions. EGM-2 medium was changed to EBM-2
(endothelial basal medium) without fetal bovine serum and growth factors, and siRNA-
transfected HUVECs were further cultured for one or two days in a hypoxic incubator
(MCO-18M, Sanyo, Japan) with 1% oxygen and 5% CO2 at 37 °C. Low oxygen content was
maintained through the controlled supply of nitrogen gas to the incubator.
RT-PCR
Gene expression profiles in siRNA-transfected HUVECs after culture under hypoxic and
serum-deprived conditions were examined with RT-PCR. Total RNA was isolated using the
RNeasy Mini kit (Qiagen, Chatsworth, CA, USA) from each sample of cells (n=4 per
group). The RNA concentration was determined by measuring absorbance at 260 nm using a
spectrophotometer. A reverse transcription reaction was performed with 1 µg pure total
RNA using SuperScript™ III reverse transcriptase (Invitrogen). The synthesized cDNA was
amplified by PCR with Platinum PCR Master Mix (Invitrogen). The sequences and product
sizes of human-specific primers are listed in Table 1. The amplification conditions followed
several steps: 5 min at 95°C, followed by 25–35 cycles of denaturing (94°C, 30 sec),
annealing (55–62°C, 30 sec), and extension (72°C, 45 sec) with a final extension at 72°C for
7 min. The PCR products were visualized by electrophoresis on a 2% agarose gel with
ethidium bromide (E-Gel, Invitrogen).
Quantitative real-time PCR (TaqMan method)
Quantitative real-time PCR was performed using a 7500 Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). Universe Fast PCR Master Mix (Applied
Biosystems) was used for PCR. Quantification of gene expression in siRNAtransfected
HUVECs was performed with TaqMan® Gene Expression Assays (Applied Biosystems) for
each target (TNFR-1: Hs00533568_g1, SHP-1: Hs00169359_m1, TNF-α: Hs00174128_m1,
VEGF: Hs00173626_m1, KDR/Flk-1: Hs00176676_m1, eNOS: Hs00167166_m1, Bcl-xL:
Hs00169141_m1, Bax: Hs00180269_m1, and GAPDH: Hs02758991_g1). The expression
level of target genes was determined by the comparative Ct method, whereby the target is
normalized to the endogenous reference (GAPDH). The Ct value is the cycle number at
which the fluorescence level reaches its threshold. The ΔCt was determined by subtracting
the Ct of GAPDH control from the Ct of target gene [ΔCt = Ct (target) - Ct (GAPDH)]. The
relative value of target to endogenous reference was described as the fold of GAPDH =
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2−ΔCt [17]. The relative expression of TNFR-1 or SHP-1 siRNA-transfected HUVECs was
normalized to that in GFP siRNA-transfected HUVECs.
Determination of apoptotic activity
One and two days after culture under hypoxic and serum-free conditions, the extent of
apoptosis of siRNA-transfected HUVECs was determined by the terminal deoxynucleotide
transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) method using a
commercially-available apoptosis detection kit (ApopTaq®, Chemicon, Temecula, CA,
USA). Cells stained with rhodamine (red) by a TUNEL staining method were counterstained
with 4,6-diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA, USA).
The stained images were examined with a fluorescence microscope (Carl Zeiss,
Oberkochen, Germany). The portion of TUNEL-positive cells among the total cell
population was calculated as the percentage ratio of TUNEL-stained cells to DAPI-stained
cells.
Cell viability measurement
Cell viability was measured using the CellTiter 96® Aqueous One Solution assay kit
(Promega, Madison, WI, USA). Cellular metabolic activity was determined by measuring
optical absorbance at 490 nm using a Victor3 Multilabel plate counter (Perkin-Elmer Life
Sciences, Boston, MA, USA). The viability of siRNA-transfected HUVECs cultured under
hypoxic (1% oxygen) and serum-free (EBM-2 medium) conditions for one or two days was
converted to percent viability by comparison to that of HUVECs cultured under normal
condition with normoxia (20% oxygen) and EGM-2 medium for the comparable time
period.
Capillary formation assay
48-well polystyrene plates were coated with Growth Factor Reduced Matrigel (GFR-
Matrigel, BD Biosciences, San Jose, CA, USA). Two days after transfection, siRNA-
transfected HUVECs were detached with 0.05% (w/v) trypsin, suspended in EBM-2 basal
medium, and seeded at 4.0 × 104/cm2 onto GFR-Matrigel-coated plates. Cells were
incubated under hypoxic (1% oxygen) and serum-deprived (EBM-2 medium) conditions at
37 °C and 5% CO2. After two days of culture, the formation of capillary structures by
HUVECs was examined microscopically.
Statistical analysis
Quantitative data are expressed as mean ± standard deviation. Statistical analysis was
performed by the unpaired Student’s t test using InStat software (InStat 3.0, GraphPad
Software Inc., San Diego, CA, USA). A value of p<0.05 was considered to be statistically
significant.
Results and Discussion
Delivery of siRNA targeting TNFR-1 or SHP-1 specifically silences each target in
HUVECs. In a preliminary transfection with GAPDH siRNA, 80% reduction of GAPDH
activity was observed in HUVECs two days after transfection. RT-PCR was performed to
confirm the silencing of each molecule in HUVECs two days after siRNA transfection (Fig.
1A). The mRNA expression of TNFR-1 or SHP-1 was significantly reduced in HUVECs
transfected with each siRNA compared to GFP siRNA-transfected or untransfected
HUVECs (Fig. 1A). Quantitative real-time PCR analysis verified that groups treated with
TNFR-1 or SHP-1 delivery resulted in 76.5 % and 97.2 % silencing, respectively, of each
target molecule relative to the control group transfected with GFP siRNA (Fig. 1B and C).
Cho et al. Page 4













Under hypoxic (1% oxygen) and serum-deprived conditions, silencing of TNFR-1 or SHP-1
expression led to an increase in the expression of angiogenic and anti-apoptotic factors and a
decrease in the expression of pro-apoptotic factor in HUVECs. Hypoxia and serum-
deprivation enhanced TNF-α and VEGF expression in HUVECs (Fig. 2A). The expressions
of TNF-α and VEGF in HUVECs transfected with TNFR-1 or SHP-1 siRNA were not
significantly different (p>0.05) from those in HUVECs transfected with GFP siRNA (Fig.
2B and C). Despite enhanced expression of TNF-α, which is known to downregulate KDR/
Flk-1 and eNOS expression in ECs [5,18,19], the expression levels of KDR/Flk-1 and eNOS
were enhanced in HUVECs with TNFR-1 or SHP-1 siRNA transfection at day one and two
after culture in the serum-deprived hypoxic condition (Fig. 2A, D, and E). Previous studies
have shown that suppression of TNFR-1 or SHP-1 might increase KDR/Flk-1 expression
[5,15]. Consequently, enhanced KDR/Flk-1 expression could increase eNOS expression
[20]. The expression of the anti-apoptotic factor (Bcl-xL) were enhanced by silencing of
TNFR-1 or SHP-1 (Fig. 2A and F), whereas the expression of the pro-apoptotic factor (Bax)
was reduced in TNFR-1 or SHP-1 siRNA-transfected HUVECs compared with GFP siRNA-
transfected HUVECs (Fig. 2A and G). These results are consistent with a previous report
demonstrating that knockdown of SHP-1 by siRNA reversed the inhibition of STAT3
activation, thereby increasing the expression of STAT3-regulated gene products such as
Bcl-2 and Bcl-xL [21]. SHP-1 has a direct effect on apoptosis in many cell types [10–12] by
binding to death receptors such as TNFR-1 and FAS-R and by blocking anti-apoptotic
signals [12,22]. Because TNFR-1 is also required to induce TNF-α -mediated apoptosis in
ECs, knockdown of TNFR-1 may inhibit EC apoptosis by neutralizing TNF-α bioactivity
[23]. Therefore, the decrease in Bax expression might result from reduction in apoptotic
signals in ECs by silencing of TNFR-1 or SHP-1.
Apoptosis of HUVECs cultured under hypoxic and serum-free conditions was significantly
reduced by silencing TNFR-1 or SHP-1 expression. Favorable changes in gene expression
profiles induced by TNFR-1 or SHP-1 siRNA delivery (Fig. 2) may inhibit EC apoptosis
and enhance EC proliferation. A cell apoptosis assay (TUNEL staining) at day two after
culture showed that apoptosis was more extensive in GFP siRNA-transfected HUVECs than
in TNFR-1 or SHP-1 siRNA-transfected HUVECs (Fig. 3A). The portion of TUNEL-
positive cells was much higher in HUVECs with GFP siRNA than in HUVECs with
TNFR-1 or SHP-1 siRNA (p<0.01, compared to GFP siRNA, Fig. 3B). Additionally,
TNFR-1 or SHP-1 siRNA-transfected HUVECs showed greater cell proliferation than GFP
siRNA-transfected HUVECs at days one and two after culture under hypoxic (1% oxygen)
and serum-deprived conditions (p<0.01, compared to GFP siRNA, Fig. 3C). In vitro culture
conditions with low oxygen content and lack of survival growth factors mimic the
microenvironment in ischemic tissues. We hypothesize that in vivo delivery of siRNA for
TNFR-1 or SHP-1 may have utility for the treatment of ischemia via their angiogenic and/or
anti-apoptotic effects on ECs. Of note, the administration of soluble TNFR-1 gene as an
antagonist to TNF-α to interrupt signal pathways dependent on TNF-α has been reported to
increase angiogenesis in ischemic tissues [14,15]. Injection of plasmid vector-based siRNA
targeting SHP-1 also significantly reduced cardiomyocyte apoptosis and the infarcted area in
ischemic myocardium [12].
The administration of siRNA targeting TNFR-1 or SHP-1 stimulated capillary formation by
HUVECs under hypoxic and serum-deprived conditions. When cultured onto GFR-Matrigel,
TNFR-1 or SHP-1 siRNA-transfected HUVECs showed more extensive capillary formation
compared to GFP siRNA-transfected HUVECs (Fig. 4A–C). The number of lumen and
tubes formed by HUVECs was significantly higher in TNFR-1 or SHP-1 siRNA group than
in GFP siRNA group (Fig. 4D and E). This result suggests that the capacity of ECs inducing
angiogenesis under ischemic conditions could be enhanced by silencing molecules with anti-
angiogenic effects, such as TNFR-1 and SHP-1. TNF-α mediates association of SHP-1 with
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KDR/Flk-1, which is reported to negatively regulate VEGF-mediated signal transduction
[5,6]. TNFR-1 activation by TNF-α also inhibits EC proliferation by VEGF signaling [15].
In the context of engineered cell therapy, angiogenic cells genetically modified with siRNAs
for anti-angiogenic factors ex vivo might afford a higher therapeutic efficacy than cells
without siRNA modification as a cell therapy source for ischemic disease treatment.
RNAi targeting for anti-angiogenic or pro-apoptotic factors may provide an alternative
therapy for treatment of ischemia. The target molecules tested in the present study would be
good candidates for RNAi therapeutics for ischemic diseases. Exploration of potential
targets that are involved in more critical signaling in ischemic pathology (e.g. PHD1, an
oxygen sensor that regulates the stability of the hypoxia-inducible factors under ischemia
[24]) should be performed together with the development of efficient delivery vehicles for
systemic or local siRNA delivery to ischemic tissues.
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Silencing of target gene (TNFR-1 and SHP-1) expression by siRNA transfection. (A) RT-
PCR of HUVECs for each target at 2 days after transfection with TNFR-1, SHP-1, or GFP
siRNA. Quantitative real-time PCR of siRNA-transfected HUVECs (n=3) for (B) TNFR-1
and (C) SHP-1. The each gene expression in TNFR-1 or SHP-1 siRNA-transfected
HUVECs was normalized to that in GFP siRNA-transfected HUVECs. TNFR-1 and SHP-1
siRNA delivery using Lipofectamine 2000 resulted in a significant and specific silencing of
each molecule’s expression compared with GFP siRNA delivery (*; p<0.01, **; p<0.05,
***; p>0.05).
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Gene expression profiles in siRNA-transfected HUVECs under hypoxic (1% oxygen) and
survival factor-deprived (EBM-2 basal medium with no serum and growth factors)
conditions. (A) RT-PCR for various molecules of siRNA-transfected HUVECs retrieved at
days 1 and 2 after culture. Quantitative real-time PCR for (B) TNF-α, (C) VEGF, (D) KDR/
Flk-1, (E) eNOS, (F) Bcl-xL, and (G) Bax. The gene expression levels of TNFR-1 or SHP-1
siRNA-transfected HUVECs (n=4) at days 1 and 2 was normalized to that in GFP siRNA-
transfected HUVECs (*; p<0.01, **; p<0.05, compared to GFP siRNA group).
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Apoptotic activity of siRNA-transfected HUVECs cultured under hypoxic (1% oxygen) and
survival factor-deprived (EBM-2 basal medium with no serum and growth factors)
conditions. (A) TUNEL staining of siRNA-transfected HUVECs at 2 days after culture
(×100). Scale bar indicates 200 µm. (B) The percentage ratio of TUNEL-positive cells to
total cells at days 1 and 2 after culture (n=4, *; p<0.01, compared to GFP siRNA group). (C)
The viability of siRNA-transfected HUVECs at days 1 and 2 after culture (n=4, *; p<0.01,
compared to GFP siRNA group).
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Capillary formation by siRNA-transfected HUVECs cultured for 2 days under hypoxic (1%
oxygen) and survival factor-deprived (EBM-2 basal medium with no serum and growth
factors) conditions. When cultured onto GFR-Matrigel, HUVECs transfected with siRNAs
for (A) TNFR-1 and (B) SHP-1 showed more extensive capillary structure formation,
compared to HUVECs transfected with (C) GFP siRNA (×100). Scale bar indicates 200 µm.
The density of (D) lumens and (E) tubes in the vascular structures generated on GFR-
Matrigel (*; p<0.01, **; p<0.05, compared to GFP-siRNA group).
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Table 1
Primer sequences and PCR product sizes for target genes
Gene Primer sequences (sense and anti-sense) Product size
TNFR-1
5′-ACC AAG TGC CAC AAA GGA AC-3′
263 bp
5′-CTG CAA TTG AAG CAC TGG AA-3′
SHP-1
5′-GGC TTC TGG GAG GAG TTT GAG-3′
452 bp
5′-CGG AGT TTG TAT TCG GTT GTG-3′
KDR/Flk-1
5′-CAA CAA GCG GAG AGG AG-3′
587 bp
5′-ATG ACG ATG GAC AAG TAC CC-3′
eNOS
5′-GTG ATG GCG AAG CGA GTG AA-3′
421 bp
5′-CCG AGC CCG AAC ACA CAG AA-3′
VEGF
5′-CTT GCC TTG CTG CTC TAC CT-3′
484 bp
5′-CCT TGC AAC GCG AGT CTG T-3′
TNF-α
5′-ATG AGC ACT GAA AGC ATG ATC-3′
700 bp
5′-TCA CAG GGC AAT GAT CCC AAA GTA GAC CTG CCC-3′
Bcl-xL
5′-TTG GAC AAT GGA CTG GTT GA-3′
780 bp
5′-GTA GAG TGG ATG GTC AGT G-3′
Bax
5′-TGG CAG CTG ACA TGT TTT CTG AC-3′
204 bp
5′-TCA CCC AAC CAC CCT GGT CTT-3′
β-actin
5′-ATC TGG CAC CAC ACC TTC TA-3′
838 bp
5′-CGT CAT ACT CCT GCT TGC TG-3′
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